Insurers face long road, high cost to cover obesity drugs after promising Wegovy heart health data

There is likely a long way to go before the U.S. sees increased insurance coverage of obesity drugs, but Novo Nordisk's new data is a meaningful start.

from Health and Science https://ift.tt/I9MV8bB
https://ift.tt/Z5A6zQH
https://ift.tt/yxZrido